-$0.55 EPS Expected for Acorda Therapeutics Inc (NASDAQ:ACOR) This Quarter
Brokerages expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings per share (EPS) of ($0.55) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Acorda Therapeutics’ earnings, with estimates ranging from ($0.86) to ($0.34). Acorda Therapeutics posted earnings per share of $0.45 during the same quarter last year, which suggests a negative year over year growth rate of 222.2%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 13th.
On average, analysts expect that Acorda Therapeutics will report full year earnings of ($2.13) per share for the current year, with EPS estimates ranging from ($2.43) to ($1.91). For the next year, analysts forecast that the company will report earnings of ($1.59) per share, with EPS estimates ranging from ($3.01) to $0.01. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.05. Acorda Therapeutics had a negative return on equity of 12.96% and a negative net margin of 155.89%. The company had revenue of $47.72 million during the quarter, compared to analysts’ expectations of $43.23 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The business’s quarterly revenue was down 66.6% compared to the same quarter last year.
Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new position in shares of Acorda Therapeutics in the third quarter worth about $33,000. Commonwealth Equity Services LLC bought a new position in shares of Acorda Therapeutics in the third quarter worth about $36,000. Comerica Bank increased its stake in shares of Acorda Therapeutics by 22.5% in the third quarter. Comerica Bank now owns 44,988 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 8,268 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Acorda Therapeutics by 171.7% in the third quarter. State of Alaska Department of Revenue now owns 36,931 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 23,336 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Acorda Therapeutics in the third quarter worth about $117,000.
Shares of NASDAQ:ACOR traded down $0.09 on Thursday, reaching $2.33. The company had a trading volume of 101,696 shares, compared to its average volume of 3,518,860. Acorda Therapeutics has a twelve month low of $1.49 and a twelve month high of $17.41. The stock has a 50-day moving average price of $1.98 and a 200 day moving average price of $3.33. The stock has a market capitalization of $113.35 million, a P/E ratio of 1.27 and a beta of 1.26. The company has a quick ratio of 3.12, a current ratio of 3.42 and a debt-to-equity ratio of 1.33.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.